Dermawan Doni, Alotaiq Nasser
Department of Applied Biotechnology, Faculty of Chemistry, Warsaw University of Technology, 00-661 Warsaw, Poland.
Health Sciences Research Center (HSRC), Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13317, Saudi Arabia.
Pharmaceutics. 2025 Feb 24;17(3):295. doi: 10.3390/pharmaceutics17030295.
: Ischemic heart disease (IHD), a leading cause of cardiovascular morbidity and mortality, continues to challenge modern medicine. (Abresham), a traditional ingredient in Unani medicine, has shown promise in cardiovascular health, but its molecular mechanisms remain poorly understood. To explore the therapeutic potential of for IHD, an integrative molecular simulation approach was applied. Network pharmacology was employed to identify the most favorable target receptor for the disease. Molecular docking simulations evaluated the binding affinities of chemical and protein-based compounds from to the selected receptor. Molecular dynamics (MD) simulations confirmed the stability of these interactions under physiological conditions. Pharmacophore modeling identified key structural features critical for bioactivity, while in silico toxicity assessments evaluated the safety profiles of the compounds. Key bioactive compounds from , including Menaquinone-7, Quercetin, and Behenic acid, showed strong interactions with the target receptor, ACE2. The MD-based MM/PBSA calculations revealed the binding free energy values of Menaquinone-7 (-35.12 kcal/mol), Quercetin (-29.38 kcal/mol), and Behenic acid (-27.76 kcal/mol), confirming their strong binding affinity. Protein-based compounds, such as Chorion class high-cysteine HCB protein 13 (-212.43 kcal/mol), Bombyxin A-5 (-209.36 kcal/mol), and FMRFamide-related peptides (-198.93 kcal/mol), also displayed promising binding affinities. In silico toxicity assessments revealed favorable safety profiles for most compounds. This study positions as a promising source of therapeutic agents for IHD. Future work should focus on experimental validation of these computational findings through in vitro and in vivo studies.
缺血性心脏病(IHD)是心血管疾病发病和死亡的主要原因,仍然是现代医学面临的挑战。阿卜勒舍姆(Abresham)是尤纳尼医学中的一种传统成分,已显示出对心血管健康有益,但对其分子机制仍知之甚少。为了探索阿卜勒舍姆对IHD的治疗潜力,应用了一种综合分子模拟方法。采用网络药理学来确定该疾病最有利的靶受体。分子对接模拟评估了阿卜勒舍姆中基于化学和蛋白质的化合物与所选受体的结合亲和力。分子动力学(MD)模拟证实了这些相互作用在生理条件下的稳定性。药效团建模确定了对生物活性至关重要的关键结构特征,而计算机模拟毒性评估则评估了化合物的安全性。阿卜勒舍姆中的关键生物活性化合物,包括维生素K2-7、槲皮素和山嵛酸,与靶受体ACE2表现出强烈的相互作用。基于MD的MM/PBSA计算揭示了维生素K2-7(-35.12千卡/摩尔)、槲皮素(-29.38千卡/摩尔)和山嵛酸(-27.76千卡/摩尔)的结合自由能值,证实了它们具有很强的结合亲和力。基于蛋白质的化合物,如绒毛膜类高半胱氨酸HCB蛋白13(-212.43千卡/摩尔)、家蚕素A-5(-209.36千卡/摩尔)和FMRF酰胺相关肽(-198.93千卡/摩尔),也显示出有前景的结合亲和力。计算机模拟毒性评估显示大多数化合物具有良好的安全性。本研究将阿卜勒舍姆定位为IHD治疗药物的一个有前景的来源。未来的工作应集中在通过体外和体内研究对这些计算结果进行实验验证。